Welcome to our dedicated page for Bespoke Extracts SEC filings (Ticker: BSPK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Bespoke Extracts, Inc. (OTCQB: BSPK), a Nevada corporation operating as The Joint Company in Colorado’s regulated cannabis market. Here, investors can review the company’s official disclosures on financial condition, capital structure, and material agreements.
Bespoke’s periodic reports and exhibits include consolidated balance sheets and statements of operations that detail sales, cost of products sold, gross profit, operating expenses, interest expense, and net loss, as well as information on assets, liabilities, and stockholders’ deficit. These filings show how the company’s pre-roll manufacturing, branded product lines, and third-party processing services are reflected in its revenue and margin profile over time.
The company also files current reports on Form 8-K to announce material events. For example, Bespoke has furnished press releases with quarterly financial results for the periods ended March 31, June 30, and September 30, 2025, and has disclosed an amendment to a senior note that extended its maturity date while leaving other material terms unchanged. Such filings provide insight into financing arrangements, debt obligations, and key operational milestones.
On Stock Titan, Bespoke’s SEC filings are supplemented with AI-powered summaries that explain the main points of lengthy documents, highlight important changes from prior periods, and help clarify technical accounting or legal language. Users can quickly scan 10-Q and 10-K disclosures, review 8-K event descriptions, and track how the company reports on its Colorado-focused cannabis operations, all with real-time updates as new documents are posted to EDGAR.
Bespoke Extracts, Inc. notified the SEC that it will file its Form 10-K for the period ended December 31, 2025 late under Rule 12b-25. The company states it needs additional time to complete compilation, review, and finalization of financial statements and related disclosures and expects to file no later than fifteen calendar days after the original due date.
The notice discloses an estimated revenue increase to $1,501,000 for the year ended December 31, 2025, up from $1,117,452 for the year ended December 31, 2024. The company is unable to provide an estimate of its net loss for 2025 in this notification.
Bespoke Extracts, Inc. insider Michael Feinsod, who serves as chief executive officer, director, and a 10% owner, filed an annual statement of changes in beneficial ownership. The filing reports two acquisitions of common stock in 2025: 1,500 shares on 09/24/2025 at $0.27 per share and 1,000 shares on 12/19/2025 at $0.20 per share. Following these transactions, Feinsod beneficially owned 2,516,112 shares of common stock at the end of the fiscal year. Of this amount, 1,501,000 shares are held directly by Feinsod and 1,015,112 shares are held by Infinity Management, LLC, where he is the managing member.
Bespoke Extracts, Inc. reported that President and Director Garth Tyler Hunter received a grant of 200,000 shares of restricted common stock on December 30, 2025. The grant was made at a stated price of $0 per share, reflecting an equity award rather than an open-market purchase. According to the filing, these restricted shares will vest one year from the grant date. After this award, Hunter directly holds 1,000,000 shares of Bespoke Extracts common stock.
Bespoke Extracts, Inc. filed a Form 8-K to report that it has released a press release covering its financial results and business highlights for the third quarter ended September 30, 2025. The press release, dated November 12, 2025, is attached as Exhibit 99.1 and incorporated by reference. The company states that the information under this item, including the exhibit, is being furnished rather than filed, which limits its exposure to certain Exchange Act liabilities.
Bespoke Extracts, Inc. reported Q3 2025 results with stronger sales but continued losses and liquidity pressure. Sales were $467,945 (up from $277,471), generating gross profit of $234,175. Operating loss narrowed to $53,891, and net loss was $78,088 or $0.01 per share.
For the first nine months, sales reached $1,121,657 with gross profit of $542,453 and a net loss of $543,715. Operating expenses declined year over year as stock-based compensation fell, partly offset by higher salaries.
Liquidity remains constrained: cash was $16,743, current liabilities were $1,872,581, and the company reported a working capital deficit of $1,675,749 and a stockholders’ deficit of $2,595,508. Management disclosed “substantial doubt” about the ability to continue as a going concern. Debt includes 15% Senior Secured Notes and a related‑party note of $849,500 (maturity extended to June 30, 2027 after quarter‑end). The company also reported material weaknesses in disclosure controls.
Bespoke Extracts, Inc. entered into an Amendment to its Senior Note with Infinity Management, LLC on October 8, 2025. The amendment extends the note’s maturity date from June 30, 2025 to June 30, 2027, giving the company two additional years before the principal is due.
The Senior Note’s principal amount of $849,500.00, interest rate, and payment obligations remain unchanged under the amendment. The agreement formalizes an earlier mutual extension made on November 11, 2024, and the full text of the amendment is provided as an exhibit to the report.